Clofarabine
Clofarabine is an intravenous injection used to treat relapsed or refractory acute lymphoblastic leukemia, particularly in pediatric patients. It belongs to the class of nucleoside metabolic inhibitors, which work by stopping cancer cells from multiplying. Manufactured by Eugia US LLC under ANDA212457, this 1 mg/mL solution is now discontinued. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Clofarabine is an intravenous injection used to treat relapsed or refractory acute lymphoblastic leukemia, particularly in pediatric patients. It belongs to the class of nucleoside metabolic inhibitors, which work by stopping cancer cells from multiplying. Manufactured by Eugia US LLC under ANDA212457, this 1 mg/mL solution is now discontinued. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Clofarabine",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Clofarabine — ANDA 207831 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207831"
}
]
|
| identifier | ANDA207831 |
| issued | 2016-09-16 |
| keyword |
[
"fda",
"health-care",
"medications",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Clofarabine |
